2017
OSIVAX - June 2017
Creation of OSIVAX, a spin-off taking over IMAXIO's R&D activity, with a €2.7 million seed funding round
IMAXIO & DKFZ - April 2017
IMAXIO signs a license agreement with the German Cancer Research Center (DKFZ)
Influenza - March 2017
IMAXIO receives scientific advice from the EMA for its influenza vaccine candidate
Creation of OSIVAX, a spin-off taking over IMAXIO's R&D activity, with a €2.7 million seed funding round
IMAXIO & DKFZ - April 2017
IMAXIO signs a license agreement with the German Cancer Research Center (DKFZ)
Influenza - March 2017
IMAXIO receives scientific advice from the EMA for its influenza vaccine candidate
2016
Trolovol® - December 2016
IMAXIO sells Trolovol in order to focus exclusively on vaccines
Leptospirosis - November 2016
Execution of a collaboration agreement with AJ Biologics to extend the commercialisation of IMAXIO's leptospirosis vaccine in Malaysia
Cancer - October 2016
Execution of a collaboration agreement with Centre Léon Bérard, and award of a grant from CLARA, for the preclinical development of an anticancer immunotherapy based on the oligoDOM® v1.0 technology
Intellectual property - May 2016
Receipt of notices of allowance from the USPTO for two new patent applications
Tuberculosis - March 2016
Publication of the results of a phase I trial of MVA85A-oligoDOM® v1.0, the first human clinical trial using the oligoDOM® technology
Malaria - January 2016
Publication of a new scientific article covering the use of the oligoDOM® technology
IMAXIO sells Trolovol in order to focus exclusively on vaccines
Leptospirosis - November 2016
Execution of a collaboration agreement with AJ Biologics to extend the commercialisation of IMAXIO's leptospirosis vaccine in Malaysia
Cancer - October 2016
Execution of a collaboration agreement with Centre Léon Bérard, and award of a grant from CLARA, for the preclinical development of an anticancer immunotherapy based on the oligoDOM® v1.0 technology
Intellectual property - May 2016
Receipt of notices of allowance from the USPTO for two new patent applications
Tuberculosis - March 2016
Publication of the results of a phase I trial of MVA85A-oligoDOM® v1.0, the first human clinical trial using the oligoDOM® technology
Malaria - January 2016
Publication of a new scientific article covering the use of the oligoDOM® technology
2015
Malaria - November 2015
Potential new vaccine candidate aims to block transmission of malaria parasites
Bellerophon project - June 2015
Call for process development and GMP manufacture of a vaccine candidate
Potential new vaccine candidate aims to block transmission of malaria parasites
Bellerophon project - June 2015
Call for process development and GMP manufacture of a vaccine candidate
2014
ANR grant - October 2014
France's National Research Agency (ANR) selects the OPTIVAC Project and contributes EUR 600,000 (USD 772,000) to improve the efficacy of influenza vaccines
IMAXIO & DKFZ - October 2014
IMAXIO signs an option for a license agreement with the German Cancer Research Center (DKFZ)
France's National Research Agency (ANR) selects the OPTIVAC Project and contributes EUR 600,000 (USD 772,000) to improve the efficacy of influenza vaccines
IMAXIO & DKFZ - October 2014
IMAXIO signs an option for a license agreement with the German Cancer Research Center (DKFZ)
2013
IMAXIO & VitamFero - October 2013
IMAXIO and VitamFero launch a R&D collaboration
Sale of the genomics division - October 2013
IMAXIO sells its genomics division to Hybrigenics to focus on its immunology business
First human clinical trial of oligoDOM® v1.0 - September 2013
IMAXIO announces the first human clinical trial using its pro-immunogenic technology oligoDOM® v1.0, in tuberculosis
FP7 grant - July 2013
Bellerophon Project awarded EUR 5.5 million by EU to develop Staphylococcus aureus vaccine
oligoDOM® in animal health - June 2013
IMAXIO signs an option for a license agreement with a leading global animal health company to develop veterinary vaccines
Trolovol® - January 2013
IMAXIO acquires Trolovol, an orphan drug indicated for a congenital metabolic disease
IMAXIO and VitamFero launch a R&D collaboration
Sale of the genomics division - October 2013
IMAXIO sells its genomics division to Hybrigenics to focus on its immunology business
First human clinical trial of oligoDOM® v1.0 - September 2013
IMAXIO announces the first human clinical trial using its pro-immunogenic technology oligoDOM® v1.0, in tuberculosis
FP7 grant - July 2013
Bellerophon Project awarded EUR 5.5 million by EU to develop Staphylococcus aureus vaccine
oligoDOM® in animal health - June 2013
IMAXIO signs an option for a license agreement with a leading global animal health company to develop veterinary vaccines
Trolovol® - January 2013
IMAXIO acquires Trolovol, an orphan drug indicated for a congenital metabolic disease
2012
IMAXIO & Merial - December 2012
Signing of an option for a licence agrement to develop an animal health vaccine
Funding - April 2012
IMAXIO closes € 2.9-million funding round
Signing of an option for a licence agrement to develop an animal health vaccine
Funding - April 2012
IMAXIO closes € 2.9-million funding round
